SCHEMBL2592055

SCHEMBL2592055

CCCCC(=O)OC(C)(C)COc1c(-c2ccc3c(c2)CNC3=O)ccc(OC)c1OC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLQ O75417 1/20 0.35
TDP2 O95551 2/20 0.35
PRF1 P14222 1/20 0.35
MAPKAPK2 P49137 1/20 0.35
GSK3B P49841 2/20 0.34
DAPK3 O43293 1/20 0.34
NTRK1 P04629 1/20 0.34
PIM1 P11309 1/20 0.34
FLT3 P36888 1/20 0.34
ROCK1 Q13464 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
PRKCI P41743 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
ADORA1 P30542 1/20 0.33
PDE4A P27815 2/20 0.32
PDE4B Q07343 2/20 0.32
PDE4C Q08493 2/20 0.32
PDE4D Q08499 2/20 0.32
CNR2 P34972 2/20 0.32
CNR1 P21554 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2591973 0.97 POLQ (0.35) POLQTDP2PRF1MAPKAPK2GSK3B
SCHEMBL14734800 0.95 PRKCI (0.36) POLQTDP2PRF1MAPKAPK2GSK3B
SCHEMBL14734754 0.91 GSK3B (0.38) POLQTDP2PRF1MAPKAPK2GSK3B
SCHEMBL2584978 0.89 POLQ (0.35) POLQTDP2PRF1MAPKAPK2GSK3B
SCHEMBL2584838 0.89 POLQ (0.37) POLQTDP2PRF1MAPKAPK2GSK3B
SCHEMBL2584358 0.88 POLQ (0.39) POLQTDP2PRF1MAPKAPK2GSK3B
SCHEMBL14734824 0.87 POLQ (0.36) POLQTDP2PRF1MAPKAPK2GSK3B
SCHEMBL14734803 0.87 GSK3B (0.36) POLQTDP2PRF1MAPKAPK2GSK3B
SCHEMBL14736916 0.86 HSD17B1 (0.41) ADORA1PDE4DCNR2CNR1
SCHEMBL14737111 0.85 TDP2 (0.39) POLQTDP2PRF1MAPKAPK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 EP disclosed
WO-2011134468-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2011-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A POLQ 1717/4885TDP2 54/4885PRF1 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.